Head-to-head comparison
| Property | Bortezomib | Carfilzomib |
|---|---|---|
| Category | Other | Other |
| Legal Status | Prescription | Prescription |
| Primary Route | intravenous | intravenous |
| Half-life | ~9–15 hours | ~1 hour (plasma); pharmacodynamic effect persists due to irreversible binding |
| Mol. Weight | 384.24 Da | 719.92 Da |
| Side Effects | Peripheral neuropathy (dose-limiting), Thrombocytopenia, Fatigue | Hypertension, Cardiac failure, Dyspnea |
Key differences
- Chemical class: Bortezomib is a boronic acid peptide that forms a slowly-reversible covalent adduct with the catalytic threonine of the 20S proteasome; carfilzomib is an epoxyketone peptide that forms an irreversible covalent bond.
- Reversibility: Bortezomib's inhibition is slowly reversible over hours, giving the proteasome time to partially recover between doses; carfilzomib's irreversible binding means recovery requires synthesis of new proteasome subunits, producing more sustained inhibition per dose.
- ENDEAVOR phase III data: In relapsed or refractory multiple myeloma, carfilzomib-dexamethasone produced superior progression-free survival compared to bortezomib-dexamethasone, supporting carfilzomib in the relapsed setting.
- CLARION phase III data: In newly diagnosed transplant-ineligible patients, carfilzomib-melphalan-prednisone did not show a PFS advantage over bortezomib-melphalan-prednisone, and carfilzomib's role in frontline transplant-ineligible therapy is less clear-cut.
- Peripheral neuropathy: Bortezomib causes clinically significant peripheral neuropathy in a substantial minority of patients, often dose-limiting and frequently requiring dose reduction or discontinuation; carfilzomib has a markedly lower peripheral neuropathy burden.
- Cardiovascular toxicity: Carfilzomib is associated with hypertension, heart failure, and acute cardiovascular events at higher rates than bortezomib, particularly in patients with preexisting cardiac disease; bortezomib's cardiac signal is lower.
- Route and dosing: Bortezomib is given subcutaneously (now preferred) or IV push, typically twice weekly or weekly; carfilzomib is IV infusion only, typically given on days 1, 2, 8, 9, 15, 16 of a 28-day cycle with dexamethasone pretreatment.
The verdict
Bortezomib and carfilzomib are both essential in modern myeloma therapy, but they are not interchangeable. Bortezomib remains the workhorse frontline proteasome inhibitor — lower cost, subcutaneous dosing, strong combination data with immunomodulators and anti-CD38 antibodies, and a better cardiovascular safety profile — though its peripheral neuropathy burden is real and often dose-limiting. Carfilzomib is favored in the relapsed and refractory setting on the strength of ENDEAVOR, particularly in patients who have developed or cannot tolerate neuropathy, and its irreversible mechanism often retains activity in bortezomib-refractory disease. The selection is driven less by pure efficacy than by line of therapy, comorbidity profile (cardiac vs neuropathic), and access constraints.
Frequently asked questions
Carfilzomib has the stronger phase III relapsed-setting evidence. ENDEAVOR directly compared carfilzomib-dexamethasone to bortezomib-dexamethasone in relapsed or refractory disease and reported superior progression-free survival for the carfilzomib arm. In the frontline transplant-ineligible setting, CLARION did not show a similar advantage, so the efficacy edge is specifically a relapsed-setting finding.
The mechanism is not fully settled, but bortezomib accumulates in dorsal root ganglia and its off-target effects on mitochondrial function and neuronal proteasome activity are thought to drive a length-dependent sensory neuropathy. Carfilzomib's narrower subunit selectivity and different tissue distribution produce a substantially lower neuropathy signal. Subcutaneous bortezomib dosing reduced but did not eliminate the neuropathy problem.
Not an absolute contraindication, but a reason for cardiac-history screening, baseline blood pressure optimization, cautious hydration, and close monitoring during the first cycles. Heart failure, hypertension, and acute ischemic events have been reported, particularly in older patients and those with preexisting cardiac disease. In many centers, patients with significant baseline cardiac dysfunction are steered toward bortezomib.
Bortezomib forms a slowly-reversible covalent adduct; proteasome activity recovers over hours. Carfilzomib's epoxyketone forms an irreversible covalent bond, so recovery requires the cell to synthesize new proteasome subunits. The practical effects are sustained inhibition per dose for carfilzomib and partial activity against bortezomib-refractory disease, offset by less dose flexibility when toxicity appears.
Yes. Ixazomib (Ninlaro) is an oral boronic acid proteasome inhibitor approved in combination with lenalidomide and dexamethasone for relapsed multiple myeloma. It offers the convenience of oral dosing but has generally produced less impressive PFS numbers than carfilzomib-based regimens in indirect comparison. Marizomib, a pan-proteasome inhibitor, has been studied but is not FDA-approved.
Proteasome inhibitors and anti-CD38 antibodies are complementary, not competing. Modern frontline regimens combine them — for example, daratumumab-bortezomib-lenalidomide-dexamethasone in transplant-eligible patients, or daratumumab-carfilzomib-dexamethasone in relapsed disease. Bortezomib and carfilzomib remain structural pillars of myeloma therapy; daratumumab is layered on top rather than substituted in.